Omeros Q1 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Source: seekingalpha
- Strong Earnings Report: Omeros reported a Q1 non-GAAP EPS of -$0.24, beating expectations by $0.15, indicating improved financial performance and boosting investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $9.89 million, exceeding expectations by $5.78 million, primarily driven by YARTEMLEA sales, reflecting increasing market acceptance of its products.
- Sales Performance: For the three months ending March 31, 2026, gross product sales of YARTEMLEA reached $11.1 million, with net sales of $9.9 million, demonstrating strong performance among U.S. wholesalers and solidifying market position.
- Future Outlook: Omeros expects YARTEMLEA to be financially self-sustaining in 2026 and targets positive cash flow in 2027, showcasing the company's confidence in future growth and strategic planning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OMER?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OMER
Wall Street analysts forecast OMER stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.640
Low
36.00
Averages
43.67
High
55.00
Current: 9.640
Low
36.00
Averages
43.67
High
55.00
About OMER
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Choices in Gene Editing and Rare Disease Treatments
- Strategic Partnership Advantage: Intellia Therapeutics' deep collaboration with Regeneron accelerates the development of CRISPR gene editing therapies, achieving approximately $67.7 million in revenue for FY 2025, reflecting a nearly 17% year-over-year growth, despite a net loss of about $412.7 million, highlighting both potential and challenges in the high-risk biotech sector.
- Commercial Transition: Omeros has entered the commercial stage with FDA approval of Yartemlea in 2025, reporting no revenue for the fiscal year, yet its partnership with Novo Nordisk offers potential milestone payments and royalties, essential for its long-term revenue strategy.
- Clinical Development Risks: Intellia's nex-z trial is on hold due to a patient death, potentially delaying approvals, while another trial's clinical hold was lifted in January 2026, illustrating the challenges posed by complex intellectual property litigation.
- Market Outlook Comparison: Omeros reported $9.89 million in Yartemlea sales in Q1 2026, with expectations to double revenue in 2027, while Intellia's promising gene editing technology faces higher investment risks due to its early-stage pipeline and ongoing losses.
See More
Choosing Between Gene Editing and Orphan Disease Treatments
- Financial Performance Comparison: Intellia Therapeutics reported approximately $67.7 million in revenue for FY 2025, reflecting a nearly 17% year-over-year growth, yet it faced a substantial net loss of $412.7 million, highlighting the high-risk, high-reward nature of gene editing.
- Product Approval and Market Outlook: Omeros transitioned to a commercial-stage company with the FDA's approval of Yartemlea in late 2025, projecting sales of $68.9 million in 2026, indicating strong market demand for its orphan disease treatment.
- Risks and Challenges: Intellia faces significant risks related to clinical development and regulatory hurdles, particularly with a key trial on hold due to a patient death, which could delay approvals, while Omeros's financial viability heavily depends on the market acceptance of Yartemlea, where any failure could materially impact its operations.
- Market Valuation Discrepancies: While Intellia is not forecasted to have earnings, its price-to-sales ratio of 28.5 contrasts sharply with Omeros's 74.2, reflecting a higher market expectation for the latter and investor confidence in Omeros's future profitability.
See More
Omeros Corporation to Host 2026 Annual Shareholders Meeting
- Shareholder Meeting Announcement: Omeros Corporation has announced that its Annual Meeting of Shareholders will be held virtually on June 18, 2026, starting at 10:00 a.m. Pacific Time, allowing shareholders to participate and ask questions via a designated website.
- Voting Eligibility Details: According to the proxy statement filed on April 30, 2026, only shareholders of record as of April 17, 2026, are entitled to vote at the meeting and any adjournments, ensuring the meeting's legitimacy and shareholder rights.
- Participation Method: Record shareholders can vote and submit questions online using a 16-digit control number provided on their proxy card, while guests without this number may attend but cannot vote or ask questions, reflecting the company's commitment to shareholder engagement.
- Company Overview: Omeros is an innovative biotechnology firm focused on developing first-in-class therapeutics for complement-mediated diseases and cancers, with its lead product YARTEMLEA already FDA-approved in the U.S., showcasing the company's strength in the biopharmaceutical sector.
See More
Omeros and SEI Investments Show High Options Trading Volume
- Omeros Options Volume: Omeros Corp (Ticker: OMER) saw options trading volume of 16,691 contracts today, representing approximately 1.7 million shares, which is about 89.8% of its average daily trading volume of 1.9 million shares over the past month, indicating strong market interest in the stock.
- High Put Option Activity: Notably, the $5 strike put option for Omeros has seen particularly high volume, with 5,116 contracts traded today, representing approximately 511,600 underlying shares, suggesting increased investor expectations for a potential decline in the stock price.
- SEI Investments Options Dynamics: In parallel, SEI Investments Company (Ticker: SEIC) recorded an options trading volume of 5,017 contracts, equivalent to approximately 501,700 shares, which accounts for about 83.7% of its average daily trading volume of 599,565 shares over the past month, reflecting sustained investor interest in the stock.
- Call Option Trading Situation: For SEIC, the $95 strike call option has shown significant activity, with 4,981 contracts traded today, representing approximately 498,100 underlying shares, indicating market confidence in the stock's potential for future appreciation.
See More
Omeros Reports Strong Q1 2026 Earnings with Positive Cash Flow
- Significant Revenue Growth: Omeros reported gross revenues of $11.1 million and net revenues of $9.9 million from YARTEMLEA product sales in Q1 2026, reflecting approximately 11% gross-to-net adjustments, indicating strong market demand and product uptake.
- Positive Cash Flow: Despite launching YARTEMLEA in mid-January, the company achieved positive cash flow in Q1 and expects to drive overall positive cash flow within 18 months, highlighting the product's market potential and profitability.
- Key Milestones: The company secured $240 million in upfront cash during Q1 and is eligible for an additional $100 million in near-term milestone payments, enhancing financial stability and future investment capacity.
- Market Access Progress: By March 31, 30 unique accounts had ordered YARTEMLEA, with 60% of the top 10 centers receiving P&T committee approval, demonstrating rapid penetration and acceptance of the product in the healthcare market.
See More
Omeros Reports Q1 Revenue Growth Following Drug Launch
- Significant Revenue Growth: Omeros reported first-quarter net product sales of $9.9 million following the U.S. launch of YARTEMLEA, a substantial increase from zero sales in the same period last year, exceeding Wall Street's estimate of $4.11 million, indicating strong market demand for the drug.
- Decline in Operating Expenses: The company's operating expenses fell sharply to $27.3 million from $35.0 million year-over-year, primarily due to reduced research and development spending, which positively impacts Omeros' financial health.
- Positive Market Reaction: Omeros shares rose over 4% in after-hours trading on Wednesday, reflecting investor optimism regarding the company's first commercial revenue, particularly given the strong early adoption of YARTEMLEA across transplant centers.
- Optimistic Future Outlook: Omeros is awaiting a European Medicines Agency decision on the YARTEMLEA marketing authorization application expected in mid-2026, which could provide further growth momentum for the company.
See More
Investment Choices in Gene Editing and Rare Disease Treatments
- Strategic Partnership Advantage: Intellia Therapeutics' deep collaboration with Regeneron accelerates the development of CRISPR gene editing therapies, achieving approximately $67.7 million in revenue for FY 2025, reflecting a nearly 17% year-over-year growth, despite a net loss of about $412.7 million, highlighting both potential and challenges in the high-risk biotech sector.
- Commercial Transition: Omeros has entered the commercial stage with FDA approval of Yartemlea in 2025, reporting no revenue for the fiscal year, yet its partnership with Novo Nordisk offers potential milestone payments and royalties, essential for its long-term revenue strategy.
- Clinical Development Risks: Intellia's nex-z trial is on hold due to a patient death, potentially delaying approvals, while another trial's clinical hold was lifted in January 2026, illustrating the challenges posed by complex intellectual property litigation.
- Market Outlook Comparison: Omeros reported $9.89 million in Yartemlea sales in Q1 2026, with expectations to double revenue in 2027, while Intellia's promising gene editing technology faces higher investment risks due to its early-stage pipeline and ongoing losses.
See More
Choosing Between Gene Editing and Orphan Disease Treatments
- Financial Performance Comparison: Intellia Therapeutics reported approximately $67.7 million in revenue for FY 2025, reflecting a nearly 17% year-over-year growth, yet it faced a substantial net loss of $412.7 million, highlighting the high-risk, high-reward nature of gene editing.
- Product Approval and Market Outlook: Omeros transitioned to a commercial-stage company with the FDA's approval of Yartemlea in late 2025, projecting sales of $68.9 million in 2026, indicating strong market demand for its orphan disease treatment.
- Risks and Challenges: Intellia faces significant risks related to clinical development and regulatory hurdles, particularly with a key trial on hold due to a patient death, which could delay approvals, while Omeros's financial viability heavily depends on the market acceptance of Yartemlea, where any failure could materially impact its operations.
- Market Valuation Discrepancies: While Intellia is not forecasted to have earnings, its price-to-sales ratio of 28.5 contrasts sharply with Omeros's 74.2, reflecting a higher market expectation for the latter and investor confidence in Omeros's future profitability.
See More
Omeros Corporation to Host 2026 Annual Shareholders Meeting
- Shareholder Meeting Announcement: Omeros Corporation has announced that its Annual Meeting of Shareholders will be held virtually on June 18, 2026, starting at 10:00 a.m. Pacific Time, allowing shareholders to participate and ask questions via a designated website.
- Voting Eligibility Details: According to the proxy statement filed on April 30, 2026, only shareholders of record as of April 17, 2026, are entitled to vote at the meeting and any adjournments, ensuring the meeting's legitimacy and shareholder rights.
- Participation Method: Record shareholders can vote and submit questions online using a 16-digit control number provided on their proxy card, while guests without this number may attend but cannot vote or ask questions, reflecting the company's commitment to shareholder engagement.
- Company Overview: Omeros is an innovative biotechnology firm focused on developing first-in-class therapeutics for complement-mediated diseases and cancers, with its lead product YARTEMLEA already FDA-approved in the U.S., showcasing the company's strength in the biopharmaceutical sector.
See More
Omeros and SEI Investments Show High Options Trading Volume
- Omeros Options Volume: Omeros Corp (Ticker: OMER) saw options trading volume of 16,691 contracts today, representing approximately 1.7 million shares, which is about 89.8% of its average daily trading volume of 1.9 million shares over the past month, indicating strong market interest in the stock.
- High Put Option Activity: Notably, the $5 strike put option for Omeros has seen particularly high volume, with 5,116 contracts traded today, representing approximately 511,600 underlying shares, suggesting increased investor expectations for a potential decline in the stock price.
- SEI Investments Options Dynamics: In parallel, SEI Investments Company (Ticker: SEIC) recorded an options trading volume of 5,017 contracts, equivalent to approximately 501,700 shares, which accounts for about 83.7% of its average daily trading volume of 599,565 shares over the past month, reflecting sustained investor interest in the stock.
- Call Option Trading Situation: For SEIC, the $95 strike call option has shown significant activity, with 4,981 contracts traded today, representing approximately 498,100 underlying shares, indicating market confidence in the stock's potential for future appreciation.
See More
Omeros Reports Strong Q1 2026 Earnings with Positive Cash Flow
- Significant Revenue Growth: Omeros reported gross revenues of $11.1 million and net revenues of $9.9 million from YARTEMLEA product sales in Q1 2026, reflecting approximately 11% gross-to-net adjustments, indicating strong market demand and product uptake.
- Positive Cash Flow: Despite launching YARTEMLEA in mid-January, the company achieved positive cash flow in Q1 and expects to drive overall positive cash flow within 18 months, highlighting the product's market potential and profitability.
- Key Milestones: The company secured $240 million in upfront cash during Q1 and is eligible for an additional $100 million in near-term milestone payments, enhancing financial stability and future investment capacity.
- Market Access Progress: By March 31, 30 unique accounts had ordered YARTEMLEA, with 60% of the top 10 centers receiving P&T committee approval, demonstrating rapid penetration and acceptance of the product in the healthcare market.
See More
Omeros Reports Q1 Revenue Growth Following Drug Launch
- Significant Revenue Growth: Omeros reported first-quarter net product sales of $9.9 million following the U.S. launch of YARTEMLEA, a substantial increase from zero sales in the same period last year, exceeding Wall Street's estimate of $4.11 million, indicating strong market demand for the drug.
- Decline in Operating Expenses: The company's operating expenses fell sharply to $27.3 million from $35.0 million year-over-year, primarily due to reduced research and development spending, which positively impacts Omeros' financial health.
- Positive Market Reaction: Omeros shares rose over 4% in after-hours trading on Wednesday, reflecting investor optimism regarding the company's first commercial revenue, particularly given the strong early adoption of YARTEMLEA across transplant centers.
- Optimistic Future Outlook: Omeros is awaiting a European Medicines Agency decision on the YARTEMLEA marketing authorization application expected in mid-2026, which could provide further growth momentum for the company.
See More
